Wealthspire Advisors LLC Has $722,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Wealthspire Advisors LLC trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 15.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 9,749 shares of the medical research company’s stock after selling 1,820 shares during the quarter. Wealthspire Advisors LLC’s holdings in Edwards Lifesciences were worth $722,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares during the last quarter. Jennison Associates LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth $555,939,000. Assenagon Asset Management S.A. grew its stake in shares of Edwards Lifesciences by 475.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after purchasing an additional 3,506,886 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Edwards Lifesciences by 239.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after purchasing an additional 2,606,950 shares during the period. Finally, Seilern Investment Management Ltd bought a new position in Edwards Lifesciences during the 4th quarter worth $109,490,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

EW opened at $71.46 on Wednesday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a market cap of $42.15 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 4.82 and a beta of 1.11. The company’s fifty day moving average price is $72.78 and its two-hundred day moving average price is $70.18. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on EW shares. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Barclays raised their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, The Goldman Sachs Group lifted their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $79.95.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,489 shares of company stock valued at $2,002,829 over the last ninety days. 1.29% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.